In Conversation: Alpha Teknova (TKNO US)
Another Brick in the Wall of Worry
Datanote: September ISM & JOLTS
Analytical Frameworks: Evaluating Payments
Citrindex Retrospective: Post September FOMC
Macro Memo: August 2024
Can You Hear Me Now?
Healthcare’s Cyclical Inflection
Citrindex Retrospective: July 2024
Global Macro Trading for Idiots: Part Four
GLP-1 Competitive Environment
In Conversation: Credo Semiconductor
Thematic Memo: Inference on Device
Interconnects 101
Citrini Retrospective: June 2024
Thematic Memo: Chevron Deference & PFAS
In Conversation: Tetra Tech Inc.
GLP-1 Check In
The Utility of Bubbles: The Intersection of Fiscal & AI
Annual Review: AI Thematic Highlights
Citrindex One-Year Anniversary
Citrindex May Update & Rebalance
High Quality H2O
Citrindex Performance Update April 2024
Market Memo: The Day After Tomorrow
Being Aware of Opposing Views
Q1 Update: Addendum
CitriniResearch Q1 Review & Outlook
Election 2024: Investment Implications & Preparations
Core Portfolio: February Performance
Biopharma Basket Bullishness & GLP-1 Developments
Citrindex: Monthly Update
Trade Retrospective: Long Cloudflare+Crowdstrike / Short Okta
Short Memo
Ratesmaggedon 2: The Ratening
State of the Themes January 2024
Market Memo: A Short Macro Insight
Citrindex Update: January 2024
24 Trades for 2024
Citrindex Performance Update
Trade Update: Holiday Edition
Global Macro Trading for Idiots: Part Two
CitrIndex Core Portfolio Performance: Updates
The Art of Being Wrong
MARKET OVERVIEW: RATES-MAGGEDON EDITION
OKTA Short & Cybersecurity Longs, Hacking Risk Frameworks
The Citrindex: Part One Redux (Investment Philosophy)
The FLOW Trial
The Citrindex: Part One
Analytical Frameworks: Evaluating Banks & Insurers
GLP-1 Thematic: News Update
Thematic Basket Chart Review
China at the Crossroads
Market Memo: Trade Recap & Ideas
State of the Themes August 2023
Global Macro Trading for Idiots
Superconductors
Long Thesis: Celestica
Thematic Investing and Mega Trends
Risk/Reward and Scenario Analysis in Trading
Upgrading from Overweight: The Effects of GLP-1 Drugs on the Investment Landscape
Artificial Intelligence: Global Equity Beneficiaries
Market Memo: Peak Reopening
